Johnson & Johnson believes that the low penetration of the soft tissue robotics market in the U.S. leaves its Ottava robotic surgical system well placed to broaden adoption. New Brunswick, N.J.-based J&J was granted FDA de novo authorization for Ottava last month, clearing the device for multiple procedures in general surgery. The company plans to launch the system first in the U.S.